Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Financial Officer | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 189,254 |
Reported balance
After 2026-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 55,137 · Balance 189,254 F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 182,842 |
Reported balance
After 2026-03-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-04 · Sale · Disposed 6,412 · Balance 182,842 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 80,674 |
Reported balance
After 2026-03-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-03 · Grant · Acquired 80,674 · Balance 80,674 F4: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
F4: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,412 | $13.31 | $85,314.22 |
DisclosureSEC source: 0002048634-26-000001 · primarydocument.xml · nonDerivative · entry 2 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,842 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 80,674 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0002048634-26-000001 · primarydocument.xml · derivative · entry 3 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,674 Underlying: Ordinary Shares · 80,674 shares Expires 2036-03-03 F4 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 55,137 | $0.00 | $0.00 |
DisclosureSEC source: 0002048634-26-000001 · primarydocument.xml · nonDerivative · entry 1 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,254 F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
| November 04, 2025 Filed Nov 4, 2025 21:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 7,033 | $12.23 | $86,013.59 |
DisclosureSEC source: 0002048634-25-000004 · primarydocument.xml · nonDerivative · entry 1 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,117 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:33 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 5,000 | $11.50 | $57,500.00 |
DisclosureSEC source: 0001562180-25-005572 · primarydocument.xml · nonDerivative · entry 3 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,150 Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:33 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 5,000 | $11.60 | $58,000.00 |
DisclosureSEC source: 0001562180-25-005572 · primarydocument.xml · nonDerivative · entry 2 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,150 Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:33 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 10,000 | $11.63 | $116,300.00 |
DisclosureSEC source: 0001562180-25-005572 · primarydocument.xml · nonDerivative · entry 1 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,150 Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 81,499 | $18.19 Strike: $18.19 | $1,482,466.81 |
DisclosureSEC source: 0001562180-25-002165 · primarydocument.xml · derivative · entry 2 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,499 Underlying: Ordinary Shares · 81,499 shares Expires 2035-03-03 F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 54,975 | $18.19 | $999,995.25 |
DisclosureSEC source: 0001562180-25-002165 · primarydocument.xml · nonDerivative · entry 1 Brackmann Christoph · CIK 0002048634 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,150 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.